ArticleNPJ vaccines2021

Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant.

Mayuresh M Abhyankar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.